Palbociclib-d8

Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

Product Specifications

CAS Number

[1628752-83-9]

Product Name Alternative

PD 0332991-d8

UNSPSC

12352005

Hazard Statement

H341, H361, H373, H411

Target

CDK; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Cell Cycle/DNA Damage; Others

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.84

Solubility

DMSO : 1mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 8.33 mg/mL (ultrasonic; warming; adjust pH to 3 with HCl; heat to 80°C)

Smiles

O=C1N(C2=NC(NC3=NC=C(C=C3)N4C([2H])(C([2H])(NC([2H])(C4([2H])[2H])[2H])[2H])[2H])=NC=C2C(C)=C1C(C)=O)C5CCCC5

Molecular Formula

C24H21D8N7O2

Molecular Weight

455.58

Precautions

H341, H361, H373, H411

References & Citations

[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3 (11) :1427-38.